Annexon IncNASDAQ:ANNX
- LAST PRICE5.1700
- TODAY'S CHANGE (%)0.0000 (0.0000%)
- Bid / Lots5.1700/ 7
- Ask / Lots5.1800/ 7
- Open / Previous Close5.1800 / 5.1700
- Day Range
- 52 Week Range
- Volume687,602
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | ANNX |
|---|---|---|
| 09:32 ET | 20008 | 5.1 |
| 09:33 ET | 3021 | 5.11 |
| 09:35 ET | 2086 | 5.19 |
| 09:37 ET | 1192 | 5.17 |
| 09:39 ET | 1950 | 5.22 |
| 09:42 ET | 2900 | 5.2258 |
| 09:44 ET | 1640 | 5.2583 |
| 09:46 ET | 5453 | 5.2389 |
| 09:48 ET | 100 | 5.235 |
| 09:50 ET | 2879 | 5.25 |
| 09:51 ET | 2355 | 5.25 |
| 09:53 ET | 6193 | 5.28 |
| 09:55 ET | 725 | 5.3 |
| 09:57 ET | 100 | 5.29 |
| 10:00 ET | 200 | 5.295 |
| 10:02 ET | 4346 | 5.25 |
| 10:04 ET | 300 | 5.26 |
| 10:06 ET | 3689 | 5.2312 |
| 10:08 ET | 200 | 5.25 |
| 10:09 ET | 4240 | 5.28 |
| 10:11 ET | 2204 | 5.26 |
| 10:13 ET | 16681 | 5.23 |
| 10:15 ET | 972 | 5.26 |
| 10:18 ET | 5671 | 5.28 |
| 10:20 ET | 3410 | 5.31 |
| 10:22 ET | 300 | 5.31 |
| 10:24 ET | 1147 | 5.3 |
| 10:26 ET | 7700 | 5.31 |
| 10:27 ET | 6294 | 5.29 |
| 10:29 ET | 400 | 5.28 |
| 10:31 ET | 78323 | 5.22 |
| 10:33 ET | 1867 | 5.2225 |
| 10:36 ET | 2320 | 5.25 |
| 10:38 ET | 2843 | 5.25 |
| 10:40 ET | 2212 | 5.28 |
| 10:42 ET | 5375 | 5.25 |
| 10:44 ET | 272 | 5.26 |
| 10:45 ET | 14700 | 5.26 |
| 10:47 ET | 7666 | 5.22 |
| 10:49 ET | 1600 | 5.21 |
| 10:51 ET | 1350 | 5.22 |
| 10:54 ET | 6902 | 5.215 |
| 10:56 ET | 600 | 5.215 |
| 10:58 ET | 11475 | 5.25 |
| 11:00 ET | 7768 | 5.255 |
| 11:02 ET | 7961 | 5.295 |
| 11:03 ET | 1100 | 5.3 |
| 11:05 ET | 1000 | 5.295 |
| 11:07 ET | 6767 | 5.29 |
| 11:09 ET | 500 | 5.285 |
| 11:12 ET | 1662 | 5.27 |
| 11:14 ET | 8774 | 5.2507 |
| 11:16 ET | 1217 | 5.26 |
| 11:18 ET | 7787 | 5.22 |
| 11:20 ET | 3419 | 5.23 |
| 11:21 ET | 5131 | 5.21 |
| 11:23 ET | 8086 | 5.23 |
| 11:25 ET | 5442 | 5.24 |
| 11:27 ET | 7950 | 5.23 |
| 11:30 ET | 4781 | 5.225 |
| 11:32 ET | 4059 | 5.24 |
| 11:34 ET | 1672 | 5.24 |
| 11:36 ET | 13690 | 5.23 |
| 11:38 ET | 1927 | 5.245 |
| 11:39 ET | 3788 | 5.23 |
| 11:41 ET | 2338 | 5.245 |
| 11:43 ET | 3300 | 5.22 |
| 11:45 ET | 200 | 5.22 |
| 11:48 ET | 4048 | 5.21 |
| 11:50 ET | 2746 | 5.22 |
| 11:52 ET | 800 | 5.215 |
| 11:54 ET | 1125 | 5.24 |
| 11:56 ET | 1200 | 5.245 |
| 11:57 ET | 700 | 5.25 |
| 11:59 ET | 4675 | 5.25 |
| 12:01 ET | 1700 | 5.23 |
| 12:03 ET | 654 | 5.245 |
| 12:06 ET | 5421 | 5.24 |
| 12:08 ET | 400 | 5.235 |
| 12:10 ET | 3285 | 5.235 |
| 12:12 ET | 100 | 5.235 |
| 12:14 ET | 13252 | 5.23 |
| 12:15 ET | 2853 | 5.235 |
| 12:17 ET | 5503 | 5.25 |
| 12:19 ET | 1532 | 5.265 |
| 12:21 ET | 2300 | 5.26 |
| 12:24 ET | 1327 | 5.265 |
| 12:26 ET | 3480 | 5.275 |
| 12:28 ET | 3751 | 5.2794 |
| 12:30 ET | 225 | 5.275 |
| 12:32 ET | 3880 | 5.25 |
| 12:33 ET | 4274 | 5.2499 |
| 12:35 ET | 3100 | 5.24 |
| 12:37 ET | 400 | 5.24 |
| 12:39 ET | 300 | 5.245 |
| 12:42 ET | 2043 | 5.24 |
| 12:44 ET | 2200 | 5.24 |
| 12:46 ET | 500 | 5.25 |
| 12:48 ET | 1300 | 5.25 |
| 12:50 ET | 2293 | 5.26 |
| 12:51 ET | 200 | 5.26 |
| 12:53 ET | 5927 | 5.2325 |
| 12:57 ET | 4586 | 5.22 |
| 01:00 ET | 100 | 5.22 |
| 01:02 ET | 327 | 5.23 |
| 01:04 ET | 896 | 5.22 |
| 01:06 ET | 2352 | 5.205 |
| 01:08 ET | 412 | 5.2 |
| 01:09 ET | 4727 | 5.21 |
| 01:11 ET | 3550 | 5.2106 |
| 01:13 ET | 2383 | 5.215 |
| 01:15 ET | 1200 | 5.215 |
| 01:18 ET | 828 | 5.22 |
| 01:20 ET | 500 | 5.215 |
| 01:22 ET | 5331 | 5.2 |
| 01:24 ET | 616 | 5.203 |
| 01:26 ET | 25835 | 5.2 |
| 01:27 ET | 2410 | 5.21 |
| 01:29 ET | 12464 | 5.21 |
| 01:31 ET | 3764 | 5.205 |
| 01:33 ET | 4121 | 5.205 |
| 01:36 ET | 1037 | 5.21 |
| 01:38 ET | 18690 | 5.23 |
| 01:40 ET | 8168 | 5.2 |
| 01:42 ET | 2008 | 5.18 |
| 01:44 ET | 200 | 5.19 |
| 01:45 ET | 1453 | 5.18 |
| 01:47 ET | 3603 | 5.13 |
| 01:49 ET | 350 | 5.14 |
| 01:51 ET | 2085 | 5.14 |
| 01:54 ET | 4965 | 5.15 |
| 01:56 ET | 300 | 5.16 |
| 01:58 ET | 1536 | 5.175 |
| 02:00 ET | 3241 | 5.175 |
| 02:02 ET | 2109 | 5.175 |
| 02:03 ET | 2118 | 5.175 |
| 02:05 ET | 1000 | 5.175 |
| 02:07 ET | 1879 | 5.161 |
| 02:09 ET | 200 | 5.17 |
Nov 15, 2024
Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4), from 4:59PM ET on Friday Nov 15, 2024 by Dow Jones
4:59PM ET on Friday Nov 15, 2024 by Dow JonesDJ Annexon Price Target Maintained With a $30.00/Share by HC Wainwright & Co., from 6:46AM ET on Friday Nov 15, 2024 by Dow Jones
6:46AM ET on Friday Nov 15, 2024 by Dow JonesDJ Annexon Price Target Maintained With a $16.00/Share by Needham, from 4:41AM ET on Friday Nov 15, 2024 by Dow Jones
4:41AM ET on Friday Nov 15, 2024 by Dow Jones
Nov 14, 2024
Annexon Reports Third Quarter 2024 Portfolio and Financial Results, and Key Anticipated Milestones, from 8:00AM ET on Thursday Nov 14, 2024 by Dow Jones
8:00AM ET on Thursday Nov 14, 2024 by Dow Jones*DJ Annexon 3Q Loss/Shr 25c >ANNX, from 8:00AM ET on Thursday Nov 14, 2024 by Dow Jones
8:00AM ET on Thursday Nov 14, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Annexon Inc | 546.2M | -5.0x | --- |
Humacyte Inc | 547.6M | -3.3x | --- |
MBX Biosciences Inc | 551.7M | 0.0x | --- |
Savara Inc | 556.0M | -7.5x | --- |
Corvus Pharmaceuticals Inc | 559.2M | -9.7x | --- |
Astria Therapeutics Inc | 527.0M | -4.6x | --- |
Company Information
Annexon, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in advancing a late-stage clinical platform of therapies for people living with classical complement-mediated neuroinflammatory diseases of the body, brain, and eye. Using its platform, it is identifying and characterizing the role of the complement pathway in three therapeutic areas: autoimmune, neurodegeneration and ophthalmology. Its lead candidate, ANX005, is an investigational monoclonal antibody (mAb), formulated for intravenous administration in a pivotal Phase III clinical trial for the treatment of patients with Guillain-Barre Syndrome (GBS). It is evaluating ANX007, an antigen-binding fragment (Fab), formulated for intravitreal administration, for the potential treatment of patients with geographic atrophy (GA). It is developing ANX1502, which is an oral small molecule for the treatment of autoimmune indications. It has developed ANX009, a C1q-blocking Fab formulated for subcutaneous delivery.
Contact Information
- Headquarters
- 1400 SIERRA POINT PARKWAY BLDG C SUITE 200BRISBANE, CA, United States 94005
- Phone
- 650-822-5500
- Fax
- 650-636-9773
Executives
- Independent Chairman of the Board
- Thomas Wiggans
- President, Chief Executive Officer, Director
- Douglas Love
- Chief Financial Officer, Executive Vice President
- Jennifer Lew
- Executive Vice President, Chief Scientific Officer
- Dean Artis
- Executive Vice President, Chief Medical Officer
- Jamie Dananberg
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $546.2M |
|---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 105.7M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 1.14 |
EPS | $-1.04 |
Book Value | $3.20 |
P/E Ratio | -5.0x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
